dc.contributor.author | Korkmaz, Funda Demirtas | |
dc.contributor.author | Turacli, Irem Dogan | |
dc.contributor.author | Esendagli, Guldal | |
dc.contributor.author | Ekmekci, Abdullah | |
dc.date.accessioned | 2023-11-16T18:29:59Z | |
dc.date.available | 2023-11-16T18:29:59Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 0301-4851 | |
dc.identifier.issn | 1573-4978 | |
dc.identifier.uri | https://doi.org/10.1007/s11033-022-07751-0 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14065/5547 | |
dc.description.abstract | Objective FoxM1 transcription factor contributes to tumor metastasis and poor prognosis in many cancers including triple-negative breast cancer (TNBC). In this study, we examined the effects of FoxM1 inhibitor Thiostrepton (THIO) alone or in combination with MEK inhibitor Selumetinib (SEL) on metastatic parameters in vitro and in vivo. Methods Cell viability was determined by MTT assay. Immunoblotting and immunohistochemistry was used to assess metastasis-related protein expressions in 4T1 cells and its allograft tumor model in BALB/c mice. In vivo uPA activity was determined by enzymatic methods. Results Both inhibitors were effective on the expressions of FoxM1, ERK, p-ERK, Twist, E-cadherin, and Vimentin alone or in combination in vitro. THIO significantly decreased 4T1 cell migration and changed the cell morphology from mesenchymal-like to epithelial-like structure. THIO was more effective than in combination with SEL in terms of metastatic protein expressions in vivo. THIO alone significantly inhibited mean tumor growth, decreased lung metastasis rate and tumor foci, however, no significant changes in these parameters were observed in the combined group. Immunohistochemically, FoxM1 expression intensity was decreased with THIO and its combination with SEL in the tumors. Conclusions This study suggests that inhibiting FoxM1 as a single target is more effective than combined treatment with MEK in theTNBC allograft model. The therapeutic efficacy of THIO should be investigated with further studies on appropriate drug delivery systems. | en_US |
dc.description.sponsorship | Scientific and Technological Research Council of Turkey, (TUBITAK) [1002116S162]; Teaching Staff Training Program of Turkey | en_US |
dc.description.sponsorship | This work was supported by the Scientific and Technological Research Council of Turkey, (TUBITAK) under Grant (number 1002116S162) and Teaching Staff Training Program of Turkey. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.relation.ispartof | Molecular Biology Reports | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Foxm1 | en_US |
dc.subject | Thiostrepton | en_US |
dc.subject | Triple Negative Breast Cancer | en_US |
dc.subject | Selumetinib | en_US |
dc.subject | Metastasis | en_US |
dc.subject | Activated Protein-Kinase | en_US |
dc.subject | Matrix Metalloproteinases | en_US |
dc.subject | Nasopharyngeal Carcinoma | en_US |
dc.subject | Inhibits Proliferation | en_US |
dc.subject | Mesenchymal Transition | en_US |
dc.subject | Master Regulator | en_US |
dc.subject | Prognostic Value | en_US |
dc.subject | Down-Regulation | en_US |
dc.subject | Foxm1 | en_US |
dc.subject | Transcription | en_US |
dc.title | Effects of thiostrepton alone or in combination with selumetinib on triple-negative breast cancer metastasis | en_US |
dc.type | article | en_US |
dc.authorid | DEMIRTAS KORKMAZ, FUNDA/0000-0003-3978-9427 | |
dc.authorid | Dogan Turacli, Irem/0000-0002-3791-3538 | |
dc.department | Ufuk Üniversitesi | en_US |
dc.identifier.doi | 10.1007/s11033-022-07751-0 | |
dc.identifier.volume | 49 | en_US |
dc.identifier.issue | 11 | en_US |
dc.identifier.startpage | 10387 | en_US |
dc.identifier.endpage | 10397 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorwosid | DEMİRTAŞ KORKMAZ, FUNDA/AET-5175-2022 | |
dc.identifier.wos | WOS:000852932600007 | en_US |
dc.identifier.scopus | 2-s2.0-85137928879 | en_US |
dc.identifier.pmid | 36097108 | en_US |